News

Filter

Current filters:

dupilumab

1 to 9 of 10 results

Regeneron and Sanofi granted breakthrough designation for dupilumab

Regeneron and Sanofi granted breakthrough designation for dupilumab

25-11-2014

US biotech Regeneron Pharmaceuticals and French pharma major Sanofi have said that the US Food and Drug…

BiotechnologyDermatologicalsdupilumabRegeneronRegulationSanofiUSA

Sanofi and Regeneron’s dupilumab gets Breakthrough designation from FDA

20-11-2014

The US Food and Drug Administration has granted Breakthrough Therapy designation to French pharma major…

BiotechnologyDermatologicalsdupilumabRegeneronRegulationSanofiUSA

Positive results for Sanofi/Regeneron’s dupilumab in asthma

Positive results for Sanofi/Regeneron’s dupilumab in asthma

11-11-2014

French pharma major Sanofi and US partner Regeneron Pharmaceuticals have released positive results from…

dupilumabFrancePharmaceuticalRegeneron PharmaceuticalsResearchRespiratory and PulmonarySanofi

Regeneron third-qtr net profit plunges despite strong sales growth

Regeneron third-qtr net profit plunges despite strong sales growth

04-11-2014

US biotech firm Regeneron posted revenue of $725.8 million for the third quarter of 2014, a rise of 22%…

alirocumabBayerBiotechnologydupilumabEyleaFinancialOphthalmicsRegeneronResearchSanofisarilumab

Sanofi and Regeneron's dupilumab meets all primary and secondary endpoints Phase IIa study

Sanofi and Regeneron's dupilumab meets all primary and secondary endpoints Phase IIa study

01-10-2014

French drug major Sanofi and US biotech company Regeneron's dupilumab has met all primary and secondary…

dupilumabFrancePharmaceuticalRegeneronResearchRespiratory and PulmonarySanofiUSA

New products will grow atopic dermatitis market to $5.6 billion by 2022

New products will grow atopic dermatitis market to $5.6 billion by 2022

15-11-2013

Atopic dermatitis therapeutic sales in nine major global markets are forecast to increase from $3.9 billion…

Anacor PharmaceuticalsChinaDermatologicalsdupilumabEuropeIndiaMarkets & MarketingPharmaceuticalRegeneronSanofiUSA

Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations

22-05-2013

French drug major Sanofi (Euronext: SAN) and US biotech partner Regeneron Pharmaceuticals (Nasdaq: REGN)…

BiotechnologydupilumabPharmaceuticalRegeneronResearchRespiratory and PulmonarySanofi

1 to 9 of 10 results

COMPANY SPOTLIGHT

Menarini

Back to top